Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review

David B Fogel, David B Fogel

Abstract

Clinical trials are time consuming, expensive, and often burdensome on patients. Clinical trials can fail for many reasons. This survey reviews many of these reasons and offers insights on opportunities for improving the likelihood of creating and executing successful clinical trials. Literature from the past 30 years was reviewed for relevant data. Common patterns in reported successful trials are identified, including factors regarding the study site, study coordinator/investigator, and the effects on participating patients. Specific instances where artificial intelligence can help improve clinical trials are identified.

Keywords: Clinical trials; Enrollment; Patient burden; Pharmaceutical trials; Recruitment; Retention.

References

    1. Abraha I., Cherubini A., Cozzolino F., De Florio R., Luchetta M.L., Rimland J.M., Folletti I., Marchesi M., Germani A., Orso M., Eusebi P., Montedori A. Deviation from intention to treat analysis in randomised trials and treatment effect estimates: meta-epidemiology study. BMJ. 2015;350:h2445.
    1. Alam H., Hartono R., Kumar A., Rahman F., Tarnikova Y., Wilcox C. Proc 7th Int Conf Doc Anal Recog. IEEE Computer Society; Edinburgh, Scotland: 2013. Web page summarization for handheld devices: a natural language approach; pp. 1153–1157.
    1. Audet L.A., Bourgault P., Rochefort C.M. Associations between nurse education and experience and the risk of mortality and adverse events in acute care hospitals: systematic review of observational studies. Int. J. Nurs. Stud. 2018;80:128–146.
    1. Babbs C.F. Choosing inclusion criteria that minimize the time and cost of clinical trials. World J. Meth. 2014;4:109–122.
    1. Baquet C.R., Elison G.L., Mishra S.I. Analysis of Maryland cancer patient participation in national cancer institute-supported cancer treatment clinical trials. J. Clin. Oncol. 2008;26:3380–3386.
    1. Bennette C.S., Ramsey S.D., McDermott C.L., Carlson J.J., Basu A., Veenstra D.L. Predicting low accrual in the National Cancer Institute's cooperative group clinical trials. JNCI (J. Natl. Cancer Inst.) 2016;108
    1. Berg B.P., Denton B.T., Erdogan S.A., Rohleder T., Huschka T. Optimal booking and scheduling in outpatient procedure centers. Comp. Op Res. 2014;50:24–37.
    1. Bernard D.S., Farr S.L., Fang Z. National estimates of out-of-pocket health care expenditure burdens among nonelderly adults with cancer: 2001 to 2008. J. Clin. Oncol. 2011;29:2821–2826.
    1. Bostock S., Steptoe A. Association between low function health literacy and mortality in older adults: longitudinal cohort study. BMJ. 2012:344.
    1. Bower P., Wallace P., Ward E., Graffy J., Miller J., Delany B., Kinmonth A.L. Improving recruitment to health research in primary care. Fam. Pract. 2009;26:391–397.
    1. Branke J., Nguyen S., Pickardt C.W., Zhang M. Automated design of production scheduling heuristics. a review. IEEE Trans. Evol. Comput. 2015;20:110–124.
    1. Burke E.K., Causmaecker D.P., Berghe G.V., Van Landeghem H. The state of the art of nurse rostering. J. Sched. 2004;7:441–499.
    1. Bryant J., Powell J. Payment to healthcare professionals for patient recruitment to trials: a systematic review. BMJ. 2005:331.
    1. Byrne M.M., Tannenbaum S.L., Gluck S., Hurley J., Antoni M. Participation in cancer clinical trials: why are patients not participating? Med. Decis. Making. 2014;34:116–126.
    1. Campbell M.K., Snowdon C., Francis D., Elbourne D., McDonald A.M., Knight R., Grant A. Recruitment torandomised trials: strategies for trial enrollment and participation study: the STEPS study. Health Technol. Assess. 2007;11:105. iii-ix.
    1. Carlisle B., Kimmelman J., Ramsay T., MacKinnon N. Unsuccessful trial accrual and human subjects protections: an empirical analysis of recently closed trials. Clin. Trials. 2015;12:77–83.
    1. Carrell D.S., Schoen R.E., Leffler D.A., Morris M., Rose S., Baer A., Crockett S.D., Gourevitch R.A., Dean K.M., Mehrotra A. Challenges in adapting existing clinical natural language processing systems to multiple, diverse health care setttings. JAMIA. 2017;24:986–991.
    1. Cartmell K.B., Bonilha H.S., Matson T., Bryant D.C., Zapka J., Bentz T.A., Ford M.E., Hughest-Halberg C., Simpson K.N., Alberg A.J. Patient participation in cancer clinical trials: a pilot test of lay navigation. Contemp. Clin. Trials Comm. 2016;3:86–93.
    1. Chang B.-H., Hendricks A.M., Slawsky M.T., Locastro J.S. Patient recruitment to a randomized clinical behavioral therapy for chronic heart failure. BMC Med. Res. Meth. 2004;4:8.
    1. Chien C.-F., Tseng F.-P., Chen C.-H. An evolutionary approach to rehabilitation scheduling. A case study. Euro. J. Op. Res. 2008;189:1234–1253.
    1. Chin Feman S.P., Nguyen L.T., Quilty M.T., Kerr C.E., Nam B.H., Conboy L.A., Singer J.P., Park M., Lembo A., Kaptchuk T.J., Davis R.B. Effectiveness of recruitment in clinical trials: an analysis of methods used in a trial for irritable bowel syndrome patients. Contemp. Clin. Trials. 2008;29:241–251.
    1. Cohen D. Rosiglitazone: what went wrong? BMJ. 2010;341:c4848.
    1. Covinsky K.E., Goldman L., Cook E.F., Oye R., Desbiens N., Reding D., Fulkerson W., Connors A.F., Lynn J., Phillips R.S. The impact of serious illness on patients' families. SUPPORT Investigators. Study to understand prognoses and preferences for outcomes and risks of treatment. J. Am. Med. Assoc. 1994;272:1839–1844.
    1. Crowther M. Phase 4 research: what happens when the rubber meets the road? ASH Education Book. 2013;2013:15–18.
    1. Cryder C., London A.J., Volpp K., Lowenstein G. Informative inducement: study payment as a signal of risk. Soc. Sci. Med. 2010;70:455–464.
    1. Csimma C., Swiontkowski M.F. Large clinical trials in musculoskeletal trauma: are they possible? Lessons learned from the international study of the use of rhBMP-2 in open tibial fractures. J. Bone Joint Surg. Am. 2005;87:218–222.
    1. D'Agostino R.B. The slippery slope of surrogate outcomes. Curr. Contr. Trials Cardiovasc. Med. 2000;1:76–78.
    1. Dansky K.H., Miles J. Patient satisfaction with ambulatory healthcare services: waiting time and filling time. Hosp. Health Serv. Adm. 1997;42:165–177.
    1. Daugherty C., Ratain M.J., Grochowski E., Stocking C., Kodish E., Mick R., Siegler M. Perceptions of cancer patients and their physicians involved in phase 1 trials. J. Clin. Oncol. 1995;13:1062–1072.
    1. Davis T.C., Holcombe R.F., Berkel H.J., Pramanik S., Divers S.G. Informed consent for clinical trials: a comparative study of standard versus simplified forms. J. Natl. Cancer Inst. 1998;90:668–674.
    1. De Wit N.J., Quartero A.O., Zuithoff A.P., Numans M.E. Participation and successful patient recruitment in primary care. J. Fam. Pract. 2001;50:97681.
    1. Demner-Fushman D., Chapman W.W., McDonald C.J. What can natural language processing do for clinical decision support? J. Biomed. Inf. 2009;42:760–772.
    1. Dickson S.A., Logan J., Hagen S., Stark D., Glazener C., McDonald A.M., McPherson G. Reflecting on the methodological challenges of recruiting to a United Kingdom-wide, multi-centre, randomised controlled trial in gynaecology outpatient settings. Trials. 2013;14:389.
    1. DiMasi J.A., Grabowski H.G., Hansen R.W. The cost of drug development. N. Engl. J. Med. 2015;372:1972.
    1. Donovan J.L., Peters T.J., Noble S., Powell P., Gillatt D., Oliver S.E., Lane J.A., Neal D.E., Hamdy F.C. Who can best recruit to randomized trials? J. Clin. Epidemiol. 2003;56:605–609.
    1. Edwards P.J., Roberts I., Clarke M.J., Diguiseppi C., Wentz R., Kwan I., Cooper R., Felix L.M., Pratap S. Methods to increase response to postal and electronic questionnaires. Cochrane Database Syst. Rev. 2009;8
    1. El-Sadr W.M., Donnell D., Beauchamp G., Hall I., Torian L.V., Zingman B., Lum G., Kharfen M., Elion R., Leider J., Gordin F.M., Elharrar V., Burns D., Zerbe A., Gamble T., Branson B. Financial incentives for linkage to care and viral suppression among HIV-positive patients. JAMA Internal Medicine. 2017;177:1083–1092.
    1. Fan W., Gordon M.D. The power of social media analysis. Commun. ACM. 2014;57:74–81.
    1. Feller S. 2015. One in Four Cancer Trials Fails to Enroll Enough Participants.
    1. Fletcher B., Georghe A., Moore D., Wilson S., Damery S. Improving the recruitment activity of clinicians in randomised controlled trials: a systematic review. BMJ Open. 2012;2
    1. Fouad M.N., Lee J.Y., Catalano P.J., Vogt T.M., Zafar S.Y., West D.W., Simon C., Klabunde C.E., Kahn K.L., Weeks J.C., Kiefe C.I. Enrollment of patients with lung and colorectal cancers onto clinical trials. J. Oncol. Pract. 2013;9(2):e40–47.
    1. Getz K. Predicting successful site performance. Appl. Clin. Trials. 2011:1–2. November 1.
    1. Getz K.A. Characterizing the real cost of site regulatory compliance. Appl. Clin. Trials. 2015;24 June 1.
    1. Getz K.A., Zuckerman R., Cropp A.B., Hindle A.L., Krauss R., Kaitlin K.I. Measuring the incidence, causes, and repercussions of protocol amendments. Drug Inf. J. 2011;45:265–275.
    1. Godskesen T., Hansson M.G., Nygren P., Nordin K., Kihlbom U. Hope for a cure and altruism are the main motives behind participation in phase 3 clinical trials. Eur. J. Canc. Care. 2014
    1. Hadden K., Holland J., James L. 2017. Understanding the Subject – plain Language IRB Informed Consents for Research, PRIM&R Adv Ethical Res Conf (Poster) San Antonio, Abstract 26.
    1. Halpern S.D., Karlawish J.H., Berlin J.A. The continuing unethical conduct of underpowered clinical trials. J. Am. Med. Assoc. 2002;288:358–362.
    1. Heneghan C., Goldacre B., Mahtani K.R. Why clinical trial outcomes fail to translate into benefits for patients. Trials. 2017;18:122.
    1. Henon C., Lissa D., Paoletti X., Thibault C., Le Tourneau C., Lanoy E., Hollebecque A., Massard C., Sorea J.-C., Postel-Vinay S. Patient-reported tolerability of adverse events in phase 1 trials. ESMO Open. 2017;2
    1. Hill N.S., Preston I.R., Roberts K.E. Patients with pulmonary arterial hypertension in clinical trials. Who are they? Proc. Am. Thorac. Soc. 2008;5:603–609.
    1. Hjorth M., Holmberg E., Rodjer S., Taube A., Westin J. Physician's attitudes toward clinical trials and their relationship to patient accrual in a Nordic multicenter study on myeloma. Contr. Clin. Trials. 1996;17:37286.
    1. Hörster L., Schlenk R.F., Stadler M., Gabriel M., Thol F., Schildmann J., Vollmann J., Rochau U., Sroczynski G., Wasem J., Ganser A., Port M., Neumann A. Cost-effectiveness of methods in personalized medicine. Results of a decision-analytic model in patients with acute myeloid leukemia with normal karyotype. Leuk. Res. 2017;62:84–90.
    1. Hripcsak G., Austin J.H.M., Alderson P.O., Friedman C. Use of natural language processing to translate clinical information from a database of 889,921 chest radiographic reports. Radiology. 2002;224:157–163.
    1. Hrobjartsson A., Thomsen A.S., Emanuelsson F., Tendal B., Hilden J., Boutron I., Ravaud P., Brorson S. Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. BMJ. 2012;344:e1119.
    1. Hughes J., Greville-Harris M., Graham C.A., Lewith G., White P., Bishop F.L. What trial participants need to be told about placebo effects to give informed consent: a survey to establish existing knowledge among patients with back pain. J. Med. Ethics. 2017;0:1–4.
    1. Hui D., Glitza I., Chisholm G., Yennu S., Bruera E. Attrition rates, reasons and predictive factors in supportive and pallative oncology clinical trials. Cancer. 2013;119:1098–1105.
    1. Hurtado-Chong A., Joeris A., Hess D., Blauth M. Improving site selection in clinical studies: a standardised, objective, multistep method and first experience results. BMJ Open. 2017;7:7.
    1. Hwang T.J., Carpenter D., Lauffenburger J.C., Wang B., Franklin J.M., Kesselheim A.S. Failure of investigational drugs in late-stage clinical development and publication of trial results. JAMA Intern. Med. 2016;176:1826–1833.
    1. Ibrahim F., Tom B.D., Scott D.L., Prevost A.T. A systematic review of randomised controlled trials in rheumatoid arthritis: the reporting and handling of missing data in composite outcomes. Trials. 2016;17:272.
    1. Institute of Medicine . National Academic Press; Washington D.C: 2010. Committee on Cancer Clinical Trials.
    1. Institute of Medicine . The National Academies Press; Washington, DC: 2012. Public Engagement and Clinical Trials: New Models and Disruptive Technologies. Work Shop Summary.
    1. Jalgaonkar S.V., Bhide S.S., Tripathi R.K., Shetty Y.C., Marathe P.A., Katkar J., Thatte U.M. An audit of protocol deviations submitted to an institutional ethics committee of a tertiary care hospital. PLoS One. 2016;11
    1. Javid S.H., Unger J.M., Gralow J.R., Moinpour C.M., Wozniak A.J., Goodwin J.W., Lara P.N., Williams P.A., Hutchins E.F., Gotay C.C., Albain K.S. A prospective analysis of the influence of older age of physician and patient decision-making when considering enrollment in breast cancer clinical trials. Oncology. 2010;17:1180–1190.
    1. Jones R.H., White H., Velazquez E.J., Shaw L.K., Pietrobon R., Panza J.A., Bonow R.O., Spoko G., O'Connor C.M., Rouleau J.-L. STICH (surgical treatment for ischemic heart failure) trial enrollment. J. Am. Coll. Cardiol. 2010;56(6):490–498.
    1. Kang H. The prevention and handling of the missing data. Korean J Anesthesiol. 2013;64:402–406.
    1. Keller J.M., Liu D., Fogel D.B. IEEE/Wiley; NY: 2016. Fundamentals of Computational Intelligence.
    1. Krieger J.L., Neil J.M., Strekalova Y.A., Sarge M.A. Linguistic strategies for improving informed consent in clinical trials among low health literacy patient. J. Natl. Cancer Inst. 2017;109:djw233.
    1. La Cour J.L., Brok J., Gotzsche P.C. Inconsistent reporting of surrogate outcomes in randomised clinical trials: cohort study. BMJ. 2010;341:c3653.
    1. Larson G. Vitals; 2018. 9th Annual Vitals Wait Time Report Released. March 22.
    1. Levett K.M., Roberts C.L., Simpson J.M., Morris J.M. Site-specific predictors of successful recruitment to a perinatal clinical trial. Clin. Trials. 2014;11:584–589.
    1. Lievre M., Menard J., Bruckert E., Cogneau J., Delahaye F., Giral P., Leitersdorf E., Luc G., Masana L., Moulin P., Passa P., Pouchain D., Siest G. Premature discontinuation of clinical trials for reasons not related to efficacy, safety, or feasibility. BMJ. 2001;322:603–606.
    1. Lincoff A.M., Tardif J.C., Neal B., Nicholls S.J., Ryden L., Schwartz G.G., Malmberg K., Buse J.B., Henry R.R., Wedel H., Wichert A., Cannata R., Grobbee D.E. Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial. Am. Heart J. 2013;166:429–434.e1.
    1. Lincoff A.M., Tardif J.C., Schwartz G.G., Nicholls S.J., Ryden L., Neal B., Malmberg K., Wedel H., Buse J.B., Henry R.R., Weichert A., Cannata R., Svensson A., Volz D., Grobbee D.E. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. J. Am. Med. Assoc. 2014;311:1515–1525.
    1. Linde K., Kriston L., Rücker G., Jamil S., Schumann I., Meissner K., Sigterman K., Schneider A. Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: systematic review and network meta-analysis. Ann. Fam. Med. 2015;13:69–79.
    1. Lopienski K. 2015. Retention in Clinical Trials -- Keeping Patients on Protocols. June 1.
    1. Lösch C., Neuhäuser M. The statistical analysis of a clinical trial when a protocol amendment changed the inclusion critera. BMC Med. Res. Meth. 2008;8:16.
    1. Lovato L.C., Hill K., Hertert S., Hunninghake D.B., Probstfield J.L. Recruitment for controlled clinical trials: literature summary and annotated bibliography. Contr. Clin. Trials. 1997;18:328–352.
    1. Luo H., Xu Y., Yue F., Zhang C., Chen C. Quality of inclusion criteria in the registered clinical trials of heart failure with preserved ejection fraction: is it time for a change? Int. J. Cardiol. 2018;254:210–214.
    1. Majhail N.S., Rizzo J.D., Hahn T., Lee S.J., McCarthy P.L., Ammi M., Denzen E., Drexler R., Flesch S., James H., Omondi N., Pedersen T.L., Murphy E., Pederson K. Pilot study of patient and caregiver out-of-pocket costs of allogenic hematopoietic cell transplantation. Bone Marrow Transplant. 2013;28:865–871.
    1. Make B. How can we assess outcomes of clinical trials: the MCID approach. COPD. 2007;4:191–194.
    1. Martinson B.C., Lazovich D., Lando H.A., Perry C.L., McGovern P.G., Boyle R.G. Effectiveness of monetary incentives for recruiting adolescents to an intervention trial to reduce smoking. Prev. Med. 2000;31:706–713.
    1. McDonald A.M., Knight R.C., Campbell M.K., Entwistle V.A., Grant A.M., Cook J.A., Elbourne D.R., Francis D., Garcia J., Roberts I., Snowdon C. What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies. Trials. 2006;7:9.
    1. McNeely E.A., Clements S.D. Recruitment and retention of the older adult into research studies. J. Neurosurg. Nurs. 1994;26:57–61.
    1. McNeil D.G. 2015. Study that Paid Patients to Take HIV Drug Fails, New York Times. Feb. 24.
    1. Mehra M., Kurpanek K., Petrizzo M., Brenner S., McCraken Y., Katz T., Gurian M. The life cycle and management of protocol deviations. Therapeut Innov Reg Sci. 2014;49:762–777.
    1. Mehta A., Awah C.U., Sonabend A.M. Topoisomerase II poisons for glioblastoma; existing challenges and opportunities to personalize therapy. Front. Neurol. 2018;9:459.
    1. Michalewicz Z., Fogel D.B. second ed. Springer; Berlin: 2004. How to Solve it: Modern Heuristics; pp. 444–449.
    1. Molnar F.J., Man-Son-Hing M., Fergusson D. Systematic review of measures of clinical significant employed in randomized controlled trials of drugs for dementia. J. Am. Geriatr. Soc. 2009;5793:536–546.
    1. Moorcraft S.Y., Marriott C., Peckitt C., Cunningham D., Chau I., Starling N., Watkins D., Rao S. Patients' willingness to participate in clinical trials and views on aspects of cancer research: results of a prospective patient survey. Trials. 2016;17:17.
    1. Morris B.J., Richards J.E., Archer K.R., Lasater M., Rabalais D., Sethi M.K., Jahangir A.A. Improving patient satisfaction in the orthopaedic trauma population. J. Orthop. Trauma. 2014;28:e80–84.
    1. Neiger B.L., Thackeray R., Van Wagenen S.A. Use of social media in health promotion. Health Promot. Pract. 2012;13:159–164.
    1. Nipp R.D., Powell E., Chabner B., Moy B. Recognizing the financial burden of cancer patients in clinical trias. Oncology. 2015;20:572–575.
    1. Oermann M.H. Effects of educational intervention in waiting room on patient satisfaction. J. Ambul. Care Manag. 2003;26:150–158.
    1. Oermann M.H., Needham C.A., Dobal M.T., Sinishaj L., Lange M.P. Filling the waiting time in the clinic with education about glaucoma. Insight. 2001;26:77–80.
    1. Okuyemi K.S., Cox L.S., Nollen N.L., Snow T.M., Kaur H., Choi W., Nazir N., Mayo M.S., Ahluwalia J.S. Baseline characteristics and recruitment strategies in a randomized clinical trial of African-American light smokers. Am. J. Health Promot. 2007;21:183–191.
    1. Ory M.G., Lipman P.D., Karlen P.L., Gerety M.B., Stevens V.J., Singh M.A., Buchner D.M., Schechtman K.B., FICSIT Group Frailty and injuries: cooperative studies of intervention techniques. Prev. Sci. 2002;3:1–22.
    1. Paasche-Orlow M.K., Taylor H.A., Brancati F.L. Readability standards for informed-consent forms compared with actual readability. NEJM. 2003;348:721–726.
    1. Pearl A., Wright S., Gamble G., Doughty R., Sharpe N. Randomised trials in general practice: a New Zealand experience in recruitment. N. Z.Med. J. 2003;116:6817.
    1. Petrovitch H., Byington R., Bailey G., Borhani P., Carmody S., Goodwin L., Harrington J., Johnson H.A., Johnson P., Jones M. Systolic hypertension in the elderly program (SHEP). Part 2: screening and recruitment. Hypertension. 1991;17:II16–23.
    1. Phillips K.A., Sakowski J.A., Trosman J., Douglas M.P., Liang S.-Y., Neumann P. The economic value of personalized medicine tests: what we know and what we need to know. Genet. Med. 2014;16:251–257.
    1. Prescott R.J., Counsell C.E., Gillespie W.J., Grant A.M., Russell I.T., Kiauka S., Colthart I.R., Ross S., Shepherd S.M., Russell D. Factors that limit the quality, number and progress of randomised controlled trials. Health Technol. Assess. 1999;3:1143.
    1. Rosbach M., Andersen J.S. Patient-experienced burden of treatment in patients with multimorbidity – a systematic review of qualitative data. PLoS One. 2017;12
    1. Sateren W.B., Trimble E.L., Abrams J., Brawley O., Breen N., Ford L., McCade M., Kaplan R., Smith M., Ungerleider R., Christian M.C. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J. Clin. Oncol. 2002;20:2109–2117.
    1. Schmidt A.F., Groenwold R.H.H., van Delden J.J.M., van der Does Y., Klungel O.H., Roes K.C.B., Hoes A.W., van der Graaf R. Justification of exclusion criteria was underreported in a review of cardiovascular trials. J. Clin. Epidemiol. 2014;67:635–644.
    1. Schroen A.T., Petroni G.R., Gray H.W.R., Cronin W., Sargent D.J., Benedetti J., Wickerham D.L., Djubegovic B., Slingluff C.L. Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clin. Trials. 2010;7:312–321.
    1. Schroll J.B., Penninga E.I., Gøtzsche P.C. Assessment of adverse events in protocols, clinical study reports, and published papers of trials of Orlistat: a document analysis. PLoS Med. 2016;13
    1. Shanley A. Preventing phase III failures. Pharmaceut. Technol. 2016;2016:24–27.
    1. Sherwin H.A., McKeown M., Evans M.F., Bhattacharyya O.K. The waiting room "wait. Can. Fam. Physician. 2013;59:479–481.
    1. Slomka J., McCurdy S., Ratliff E., Timpson P., Williams M. Perceptions of financial payment for research participation among African-American drug users in HIV studies. J. Gen. Intern. Med. 2007;10:1403–1409.
    1. Sood A., Prasad K., Chhatwani L., Shinozaki E., Cha S.S., Loehrer L.L., Wahner-Roedler D.L. Patients' attitudes and preferences about participation and recruitment strategies in clinical trials. Mayo Clin. Proc. 2009;84:243–247.
    1. Stensland K.D., McBride R.B., Latif A., Wisnivesky J., Hendricks R., Roper N., Boffetta P., Hall S.J., Oh W.K., Galsky M.D. Adult cancer clinical trials that fail to complete: an epidemic? JNCI (J. Natl. Cancer Inst.) 2014;106:dju299. doi: 10.1093/jnci/dju229.
    1. Stergiopoulos S., Calvert S.B., Brown C.A., Awatin J.A., Tenaerts P., Holland T.L., DiMasi J.A., Getz K.A. Cost drivers of a hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia phase 3 clinical trial. Clin. Infect. Dis. 2018;66:72–80.
    1. Stump T.K., Eghan N., Engleston B.L., Hamilton O., Pirollo M., Schwartz J.S., Armstrong K., Beck J.R., Meropol N.J., Wong Y.-N. Cost concerns of patients with cancer. J Oncol Pract. 2013;9:251–257.
    1. Taboada M., Brooke J., Tofiloski M., Voll K., Stede M. Lexicon-based methods for sentiment analysis. Comput. Ling. 2011;37:267–307.
    1. Talarico L., Chen G., Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J. Clin. Oncol. 2004;22:4626–4631.
    1. Taylor R.W., Zimmerman J.L., Dellenger R.P., Straube R.C., Criner G.J., Davis K., Kelly K.M., Smith T.C., Small R.J. Inhaled nitric oxide in ARDS study group. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. J. Am. Med. Assoc. 2004;291:1603–1609.
    1. Thoma A., Farrokhyar F., McKnight L., Bhandari M. How to optimize patient recruitment. Can. J. Surg. 2010;53:205–210.
    1. Tong C.H., Tong L.-I., Tong J.E. The Vioxx recall case and comments. Compet. Rev. 2009;19:114–118.
    1. Townsley C.A., Selby R., Siu L.L. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J. Clin. Oncol. 2005;33:3112–3124.
    1. Twaddell S. Surrogate outcome markers in research and clinical practice. Aust. Prescr. 2009;32:47–50.
    1. Twigg D., Duffield C., Bremner A., Rapley P., Finn J. Impact of skill mix variations of patient outcomes following implementation of nursing hours per patient day staffing: a retrospective study. J. Adv. Nurs. 2012;68:2710–2718.
    1. Ulrich C.M., Knafl K.A., Ratcliff S.J., Richmond T.S., Grady C., Miller-Davis C., Wallen G.R. Developing a model of the benefits and burdens of research participation in cancer clinical trials. AJOB Prim Res. 2012;3:10–23.
    1. van den Bor R.M., Grobbee D.E., Oosterman B.J., Vaessen P.W.J., Roes K.C.B. Predicting enrollment performance of investigational centers in phase III multi-center clinical trials. Contemp Clin Trials Comm. 2017;7:208–216.
    1. Verster J., van de Loo A.J., Roehrs T., Roth T. Are clinical trial participants representative for patients with insomnia? Sleep. 2017;40:A148.
    1. Ward P.R., Rokkas P., Cenko C., Pulvirenti M., Dean N., Carney A.S., Meyer S. Waiting for" and "waiting in" public and private hospitals: a qualitative study of patient trust in South Australia. BMC Health Serv. Res. 2017;17:333.
    1. Wieseler B., Wolfram N., McGauran N., Kerekes M.F., Vervolgyi V., Kohlepp P., Kamphuis M., Groven U. Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data. PLoS Med. 2013;10
    1. Williams R.J., Tse T., DePiazza K., Zarin D. Terminated trials in the results database: evaluation of availability of primary outcome data and reasons for termination. PLoS One. 2015;10
    1. Wilson S., Bremner A., Hauck Y., Finn J. The effect of nurse staffing on clinical outcomes of children in hospital: a systematic review. Int. J. Evid. Base. Healthc. 2011;9:97–121.
    1. Yen W. Washington State Health Services Research Project; 2013. How Long and How Far Do Adults Travel for Primary Care? Research Brief No. 70. (April)
    1. Zafar S.Y., Peppercorn J.M., Schrag D., Taylor D.H., Goetzinger A.M., Zhong X., Abernethy A.P. The financial toxicity of cancer treatment. A pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncology. 2013;18:381–390.
    1. Zardavas D., Piccart-Gebhart M. Am Soc Clin Oncol Educ Book; 2015. Clinical Trials of Precision Medicine through Molecular Profiling: Focus on Breast Cancer; pp. e183–190.
    1. Ziv S. Newsweek; 2017. How to Design a Better Clinical Trial with the Patient Experience in Mind. July 21.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren